DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Feb. 01, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 13, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
Company remains on track to report topline results in Spring 2018 DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Dec. 04, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Nov. 30, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
- Positive topline results from pivotal LEAP 1 trial announced in September, with read-out from second Phase 3 trial, LEAP 2, expected in the spring of 2018 - - $112.7 million cash and investments as of September 30, 2017 - DUBLIN, Ireland , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Oct. 25, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 28, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 20, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a biopharmaceutical company engaged in the research and development of new medicines to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at a public offering price of $8.50 per share.
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $80.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an
